Giovanni Gaudino

List of Publications by Year
in descending order

77 papers	6,330 citations	81900 39 h-index	106344 65 g-index
78 all docs	78 docs citations	78 times ranked	7492 citing authors

#	Article	IF	Citations
1	Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics, 2011, 43, 1022-1025.	21.4	924
2	BAP1 and cancer. Nature Reviews Cancer, 2013, 13, 153-159.	28.4	522
3	Cellular and molecular facets of keratinocyte reepithelization during wound healing. Experimental Cell Research, 2005, 304, 274-286.	2.6	329
4	BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature, 2017, 546, 549-553.	27.8	308
5	High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma. Journal of Thoracic Oncology, 2015, 10, 565-576.	1.1	282
6	BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. Journal of Translational Medicine, 2012, 10, 179.	4.4	268
7	MicroRNA regulation of core apoptosis pathways in cancer. European Journal of Cancer, 2011, 47, 163-174.	2.8	246
8	Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma. Cancer Research, 2012, 72, 3290-3301.	0.9	213
9	Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13618-13623.	7.1	196
10	MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 312-319.	2.9	155
11	Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discovery, 2020, 10, 1103-1120.	9.4	144
12	Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids. Journal of Biological Chemistry, 2008, 283, 13021-13030.	3.4	130
13	High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13432-13437.	7.1	130
14	Advances in the systemic therapy of malignant pleural mesothelioma. Nature Clinical Practice Oncology, 2008, 5, 136-147.	4.3	124
15	HMGB1 as a therapeutic target in disease. Journal of Cellular Physiology, 2021, 236, 3406-3419.	4.1	123
16	Germline BAP1 mutations induce a Warburg effect. Cell Death and Differentiation, 2017, 24, 1694-1704.	11.2	105
17	A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. Journal of Clinical Oncology, 2018, 36, 3485-3494.	1.6	104
18	RNF168, a new RING finger, MIU-containing protein that modifies chromatin by ubiquitination of histones H2A and H2AX. BMC Molecular Biology, 2009, 10, 55.	3.0	101

#	Article	IF	Citations
19	Tumour predisposition and cancer syndromes as models to study geneâ€“environment interactions. Nature Reviews Cancer, 2020, 20, 533-549.	28.4	93
20	Bortezomib Inhibits Nuclear Factor-ÎºBâ€“Dependent Survival and Has Potent In vivo Activity in Mesothelioma. Clinical Cancer Research, 2007, 13, 5942-5951.	7.0	90
21	In Vivo Activation ofmetTyrosine Kinase by Heterodimeric Hepatocyte Growth Factor Molecule Promotes Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1857-1865.	2.4	89
22	Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the ron receptor. Oncogene, 1998, 17, 741-749.	5.9	88
23	Continuous Exposure to Chrysotile Asbestos Can Cause Transformation of Human Mesothelial Cells via HMGB1 and TNF-Î± Signaling. American Journal of Pathology, 2013, 183, 1654-1666.	3.8	88
24	Estrogen Receptor-Î² Affects the Prognosis of Human Malignant Mesothelioma. Cancer Research, 2009, 69, 4598-4604.	0.9	87
25	SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure. Cancer Research, 2005, 65, 5256-5262.	0.9	81
26	Evaluation of clonal origin of malignant mesothelioma. Journal of Translational Medicine, 2014, 12, 301.	4.4	80
27	CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma. Clinical Cancer Research, 2012, 18, 5352-5363.	7.0	78
28	Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genetics, 2015, 11, e1005633.	3.5	76
29	The zeta potential of mineral fibres. Journal of Hazardous Materials, 2014, 276, 469-479.	12.4	68
30	The Presence of Simian-Virus 40 Sequences in Mesothelioma and Mesothelial Cells Is Associated with High Levels of Vascular Endothelial Growth Factor. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 189-193.	2.9	67
31	Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts. Clinical Cancer Research, 2008, 14, 541-548.	7.0	65
32	Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Translational Lung Cancer Research, 2017, 6, 259-269.	2.8	54
33	Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25543-25552.	7.1	53
34	Simian virus 40 infectionin lymphoproliferative disorders. Lancet, The, 2003, 361, 88-89.	13.7	52
35	Macrophage Stimulating Protein (MSP) evokes superoxide anion production by human macrophages of different origin. British Journal of Pharmacology, 2001, 134, 1285-1295.	5.4	51
36	How asbestos and other fibers cause mesothelioma. Translational Lung Cancer Research, 2020, 9, S39-S46.	2.8	49

#	Article	IF	Citations
37	c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene, 2003, 22, 3669-3679.	5.9	47
38	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax, 2007, 62, 690-695.	5.6	46
39	HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget, 2017, 8, 22649-22661.	1.8	43
40	Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Review of Respiratory Medicine, 2011, 5, 683-697.	2.5	40
41	Alpha- and betapapillomavirus E6/E7 genes differentially modulate pro-inflammatory gene expression. Virus Research, 2007, 124, 220-225.	2.2	38
42	Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opinion on Emerging Drugs, 2009, 14, 423-437.	2.4	33
43	Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33466-33473.	7.1	30
44	Targeting Î±7-nicotinic receptor for the treatment of pleural mesothelioma. European Journal of Cancer, 2008, 44, 2296-2311.	2.8	29
45	Ranpirnase Interferes with NF-ÂB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth. Genes and Cancer, 2011, 2, 576-584.	1.9	28
46	Geldanamycins Trigger a Novel Ron Degradative Pathway, Hampering Oncogenic Signaling*. Journal of Biological Chemistry, 2006, 281, 21710-21719.	3.4	25
47	Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation. Current Cancer Drug Targets, 2010, 10, 176-191.	1.6	21
48	Numerous Iron-Rich Particles Lie on the Surface of Erionite Fibers from Rome (Oregon, USA) and Karlik (Cappadocia, Turkey). Microscopy and Microanalysis, 2015, 21, 1341-1347.	0.4	20
49	Recent Insights Emerging from Malignant Mesothelioma Genome Sequencing. Journal of Thoracic Oncology, 2015, 10, 409-411.	1.1	19
50	FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. Journal of Translational Medicine, 2017, 15, 58.	4.4	19
51	Mesothelioma developing in carriers of inherited genetic mutations. Translational Lung Cancer Research, 2020, 9, S67-S76.	2.8	19
52	The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. Oncogene, 2000, 19, 5208-5211.	5.9	17
53	Fowlpoxâ€based survivin vaccination for malignant mesothelioma therapy. International Journal of Cancer, 2013, 133, 612-623.	5.1	16
54	Increasing Dietary Selenium Elevates Reducing Capacity and ERK Activation Associated with Accelerated Progression of Select Mesothelioma Tumors. American Journal of Pathology, 2014, 184, 1041-1049.	3.8	16

#	Article	IF	Citations
55	Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approachesâ€"a narrative review. Precision Cancer Medicine, 2021, 4, 27-27.	1.8	15
56	Preclinical development of HIvax: Human survivin highly immunogenic vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 1585-1595.	3.3	14
57	BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene Ã— environment interaction with asbestos. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
58	BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. PLoS ONE, 2013, 8, e65489.	2.5	13
59	HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis. Biomedicines, 2014, 2, 327-344.	3.2	12
60	Microâ€Raman spectroscopy identifies crocidolite and erionite fibers in tissue sections. Journal of Raman Spectroscopy, 2013, 44, 1440-1445.	2.5	11
61	Tissue Tropism of SV40 Transformation of Human Cells: Role of the Viral Regulatory Region and of Cellular Oncogenes. Genes and Cancer, 2010, 1, 1008-1020.	1.9	10
62	Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?. Journal of Thoracic Oncology, 2019, 14, 157-159.	1.1	8
63	The therapeutic potential of the novel ribonuclease ranpirnase (OnconaseÂ®) in the treatment of malignant mesothelioma. Oncology Reviews, 2008, 2, 61-65.	1.8	4
64	Transforming growth factor-Î² released by PPD-presenting malignant mesothelioma cells inhibits interferon-Î³ synthesis by an anti-PPD CD4+ T-cell clone. International Journal of Molecular Medicine, 2003, 11, 161.	4.0	3
65	Molecular targets in cancer therapy: the Ron approach. Oncology Reviews, 2008, 1, 215-224.	1.8	2
66	Abstract 1179: Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred, tracing back nine generations to a common ancestor from the 1700s. Cancer Research, 2016, 76, 1179-1179.	0.9	2
67	Abstract 2600: HMGB1, a potential new target for mesothelioma therapy. , 2011, , .		1
68	Recent Advances in the Genomic and Proteomic Researches on Mesothelioma: What Are Novel Insights into Mesothelioma Biology?. Respiratory Disease Series, 2021, , 137-149.	0.0	0
69	Biomolecular Pathways in Mesothelioma: What Is New Perspective on Biomolecular Research for Mesothelioma?. Respiratory Disease Series, 2021, , 43-52.	0.0	0
70	Abstract 4579: CSPG4 monoclonal antibodies inhibit the growth of human malignant mesothelioma. , 2011, , .		0
71	Abstract 1557: High mobility group box 1 secretion supports tumor progression of human malignant mesothelioma. , 2012, , .		0
72	Abstract 2514: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. , 2012, , .		0

#	Article	IF	Citations
73	Abstract 3588: Common and different effects induced in primary human mesothelial cells and mice exposed to chrysotile or crocidolite asbestos.. , 2013, , .		0
74	Abstract 5557: BoxA and ethyl pyruvate offer novel therapeutic approaches for human malignant mesothelioma.. , 2013, , .		0
75	Abstract 3188: Evaluation of clonal origin of malignant mesothelioma/polyclonal origin of malignant mesothelioma. , 2014, , .		0
76	Abstract 446: BAP1 mutation in mesothelioma and â€œBAP1 Cancer Syndromeâ€• , 2014, , .		0
77	Abstract 3944: High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. , 2015, , .		0